相关实验视频

Updated: Feb 28, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

对代谢功能障碍相关的稳态性肝病的全球视角:从分子机制到治疗策略创新创新

Yanhao Qiu¹, Juan Carlos Laguna^1,2,3, Marta Alegret^1,2,3

¹Department of Pharmacology, Toxicology and Therapeutic Chemistry, School of Pharmacy and Food Science, University of Barcelona, 08028 Barcelona, Spain.

|February 27, 2026

概括

代谢功能障碍相关的脂肪性肝病 (MASLD) 涉及复杂的途径和性变态. 了解这些因素对于开发有效的组合疗法来解决这一全球性健康问题至关重要.

科学领域:

肝病学和代谢研究.
心血管疾病的发病因子心血管疾病的发病因子

背景情况:

代谢功能障碍相关的性肝病 (MASLD) 是与代谢综合征相关的日益严重的全球健康问题.
心血管疾病是MASLD患者死亡的主要原因.

研究的目的:

审查MASLD的多因素病原性,包括其性二态性.
讨论MASLD研究中使用的关键实验模型.
突出转向组合疗法的转变和需要精细的临床前模型.

主要方法:

文献综述综合了关于MASLD的当前知识.
相互连接的致病途径的分析 (脂质生成,胰岛素耐药性,线粒体功能障碍,肠道失调,铁).
检查性二态的影响 (生理学,荷尔蒙,遗传学,微生物组).
评估饮食诱导的动物模型 (主要是大鼠) 用于MASLD研究.

主要成果:

MASLD的发病包括失调的脂质生成,胰岛素抵抗,线粒体功能障碍,肠道失调,铁亡以及遗传因素.
这些机制有助于肝损伤,加速动脉样硬化.
在MASLD中存在显著的性二态,受到各种生物和环境因素的影响.
饮食诱导的老鼠模型有效地模仿了人类的MASLD特征.

结论:

MASLD是一种复杂的疾病,需要多方面的治疗策略,超越单一疗法.
完善临床前模型对于促进MASLD的理解和治疗至关重要.
在研究和治疗中解决性二态是改善患者治疗结果的关键.

关键词:

马斯尔德马斯尔德是什么意思动物模型动物模型病变的发生和发病.性二态性质性质二态性质性质二态性质治疗药物治疗药物

更多相关视频

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Liver Physiology

Liver Physiology

The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...

Overview of Lipid Metabolism

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...